ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gilead Sciences’ MAA for chronic hepatitis C therapy validated in Europe
January 25, 2017The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorisation application (MAA) for investigational Chronic Hepatitis C Therapy Sofosbuvir / Velpatasvir / Voxilaprevir (SOF / VEL / VOX). -
EMA validates Gilead’s MAA for investigational chronic Hep C therapy
January 24, 2017Sofosbuvir/Velpatasvir/Voxilaprevir cranted an accelerated assessment by the EMA. -
How Would Gilead Keep Its Status With the Increasing Downward Pressure on Revenue Expectations?
January 06, 2017Gilead has dominated the HCV drug market for years with unshakeable “absolute supremacy” since its new direct-acting antiviral (DAA) Sovaldi entered the market in December 2013.
Pharma Sources Insight January 2025
